持续的脏衍生的IgM优先识别XVIII因子A2和C2域表位,但不会改变抗体的产生
Elizabeth S York1, Benjamin D Dratch2, Jasmine Ito3
1Department of Pediatrics, Stanford University, Palo Alto, California, USA; Department of Pediatrics, Emory University, Atlanta, Georgia, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Journal of thrombosis and haemostasis : JTH
|October 30, 2024
概括
在血友病A中对因子VIII (FVIII) 的持久性IgM抗体似乎不会影响有害IgG抑制剂的发展. 这些IgM抗体结合特定的FVIII域,但不会改变抑制剂的形成.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 生物化学 生物化学
背景情况:
- 血友病A患者在抗因子VIII (FVIII) 替代疗法时会产生中和IgG抑制剂.
- 特定于FVIII的IgM存在于血友病A患者中,但它们在抑制剂发育中的作用尚不清楚.
研究的目的:
- 在A型血友病小鼠中描述FVIII特异性IgM结合相互作用.
- 评估IgM对IgG对FVIII抗体的产生的影响.
主要方法:
- 使用混合体技术从FVIII淘汰小鼠中分离和净化单克隆抗体 (mAbs).
- 通过流体相ELISA和计算建模 (高模糊性驱动的蛋白质-蛋白质 DOCKing) 评估了结合相互作用.
主要成果:
- 从13个独特的B细胞克隆中鉴定出16种猪交叉反应,非抑制的FVIII特异性IgM mAbs.
- IgM显示出对FVIII的多克隆和多活性结合,与A2和C2域相互作用.
- 服用IgM并没有影响新的FVIII抗体的产生.
结论:
- 持久性FVIII特异性IgM具有多克隆性,并优先结合FVIII的A2和C2域.
- FVIII/IgM免疫复合体的形成不会显著影响血友病A的抑制剂发育.
更多相关视频
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
14.0K
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
9.4K
相关概念视频
Transcytosis of IgG
2.7K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.7K
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
